Zentalis Pharmaceuticals (ZNTL) Net Income towards Common Stockholders (2019 - 2026)

Zentalis Pharmaceuticals' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$35.4 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 26.78% year-over-year to -$35.4 million; the TTM figure through Mar 2026 stood at -$124.1 million (up 44.63% YoY), while the FY2025 annual figure was -$137.1 million, up 17.37% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$35.4 million, roughly flat from -$35.2 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $10.0 million in Q1 2024, with the low at -$98.9 million in Q2 2023.
• The 5-year median for Net Income towards Common Stockholders is -$48.3 million (2025), against an average of -$49.1 million.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders jumped 116.47% in 2024, then slumped 580.87% in 2025.
• Zentalis Pharmaceuticals' Net Income towards Common Stockholders stood at -$48.2 million in 2022, then retreated by 26.53% to -$60.9 million in 2023, then rose by 22.1% to -$47.5 million in 2024, then increased by 25.82% to -$35.2 million in 2025, then dropped by 0.39% to -$35.4 million in 2026.
• Business Quant data shows ZNTL's Net Income towards Common Stockholders at -$35.4 million in Q1 2026, -$35.2 million in Q4 2025, and -$26.7 million in Q3 2025.